Harrow Health Inc
NASDAQ:HROW

Watchlist Manager
Harrow Health Inc Logo
Harrow Health Inc
NASDAQ:HROW
Watchlist
Price: 42.9 USD -2.23% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Harrow Health Inc?
Write Note

Harrow Health Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Harrow Health Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Harrow Health Inc
NASDAQ:HROW
Long-Term Debt
$186.1m
CAGR 3-Years
38%
CAGR 5-Years
71%
CAGR 10-Years
81%
Johnson & Johnson
NYSE:JNJ
Long-Term Debt
$31.3B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
9%
Bristol-Myers Squibb Co
NYSE:BMY
Long-Term Debt
$48.7B
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
21%
Pfizer Inc
NYSE:PFE
Long-Term Debt
$57.5B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Long-Term Debt
$35B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Long-Term Debt
$29B
CAGR 3-Years
23%
CAGR 5-Years
16%
CAGR 10-Years
19%
No Stocks Found

Harrow Health Inc
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 182 full-time employees. The company went IPO on 2013-02-08. The firm owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The firm holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The firm also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

HROW Intrinsic Value
45.19 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Harrow Health Inc's Long-Term Debt?
Long-Term Debt
186.1m USD

Based on the financial report for Sep 30, 2024, Harrow Health Inc's Long-Term Debt amounts to 186.1m USD.

What is Harrow Health Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
81%

Over the last year, the Long-Term Debt growth was 2%. The average annual Long-Term Debt growth rates for Harrow Health Inc have been 38% over the past three years , 71% over the past five years , and 81% over the past ten years .

Back to Top